Novavax Inc. has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi in the European Union. This transfer allows Sanofi to take full responsibility for commercial and regulatory activities related to Nuvaxovid in the EU and triggered a $25 million milestone payment to Novavax under their collaboration and license agreement. Novavax is also eligible for additional milestone payments and royalties based on future sales, technology transfers, and the development of new products utilizing its Matrix-M adjuvant. The partnership aims to expand the reach of protein-based, non-mRNA COVID-19 vaccines and support further vaccine innovation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH91868) on October 07, 2025, and is solely responsible for the information contained therein.